307 related articles for article (PubMed ID: 11202454)
1. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.
Hoegerle S; Altehoefer C; Ghanem N; Brink I; Moser E; Nitzsche E
Eur J Nucl Med; 2001 Jan; 28(1):64-71. PubMed ID: 11202454
[TBL] [Abstract][Full Text] [Related]
2. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
4. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
Hoegerle S; Altehoefer C; Ghanem N; Koehler G; Waller CF; Scheruebl H; Moser E; Nitzsche E
Radiology; 2001 Aug; 220(2):373-80. PubMed ID: 11477239
[TBL] [Abstract][Full Text] [Related]
5. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
7. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
Treglia G; Castaldi P; Villani MF; Perotti G; de Waure C; Filice A; Ambrosini V; Cremonini N; Santimaria M; Versari A; Fanti S; Giordano A; Rufini V
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169
[TBL] [Abstract][Full Text] [Related]
9. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature.
Gotthardt M; Battmann A; Höffken H; Schurrat T; Pollum H; Beuter D; Gratz S; Béhé M; Bauhofer A; Klose KJ; Behr TM
Nucl Med Commun; 2004 May; 25(5):439-43. PubMed ID: 15100501
[TBL] [Abstract][Full Text] [Related]
11. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
12. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.
Gotthardt M; Béhé MP; Beuter D; Battmann A; Bauhofer A; Schurrat T; Schipper M; Pollum H; Oyen WJ; Behr TM
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1273-9. PubMed ID: 16832634
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
14. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
[TBL] [Abstract][Full Text] [Related]
15. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
16. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Beheshti M; Pöcher S; Vali R; Waldenberger P; Broinger G; Nader M; Kohlfürst S; Pirich C; Dralle H; Langsteger W
Eur Radiol; 2009 Jun; 19(6):1425-34. PubMed ID: 19156423
[TBL] [Abstract][Full Text] [Related]
17. [
Rasul S; Hartenbach S; Rebhan K; Göllner A; Karanikas G; Mayerhoefer M; Mazal P; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2159-2169. PubMed ID: 29766245
[TBL] [Abstract][Full Text] [Related]
18. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
[TBL] [Abstract][Full Text] [Related]
19. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
[TBL] [Abstract][Full Text] [Related]
20. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]